MSICS Pharma
MSICS Pharma is an Israeli biotechnology company that operates a GMP production facility for naturally-sourced psilocybin. Their lead candidate MSX-06, a naturally-sourced psilocybin formulation, is in Phase 2 clinical development targeting treatment-resistant depression and obsessive-compulsive disorder.
Development Programmes
1MSX-06 (Natural Psilocybin GMP)
PsilocybinTreatment-resistant depression / OCD / anxiety / eating disorders / PTSD
Programme Tracker
Treatment-Resistant Depression (TRD)
Israeli Ministry of Health approved clinical trial for OCD and depression; Phase 2 recruiting; PTSD study call for proposals in review; GMP production facility operational in Ness Ziona
Milestones
Company milestone
In progressPTSD clinical study call for proposals using MSX-06 — moved into review and selection phase
Why it matters: Expanding MSX-06 indications beyond depression/OCD into PTSD. Israel's military population provides a large PTSD patient base for clinical recruitment.
Watch next: PTSD study site selection; Phase 2 OCD/depression enrollment milestones; international expansion plans
Company milestone
CompletedActual: Jan 1, 2022
MSiCS Pharma founded in Ness Ziona, Israel; GMP production facility for naturally-sourced (mushroom-derived) psilocybin established
Why it matters: MSiCS differentiates by producing naturally-sourced psilocybin via GMP mushroom cultivation rather than chemical synthesis. Leveraging Israel's progressive cannabis regulatory framework as a model for psilocybin clinical development.
Funding milestone
CompletedActual: Jan 1, 2023
$500K seed round from Fusion VC and GlenRock Israel
Why it matters: Very early-stage capitalization. Modest seed funding but sufficient for Israeli regulatory pathway and GMP facility setup. Eyal Gura (co-founder of Zebra Medical Vision) is connected as investor/advisor.
regulatory-designation
CompletedActual: Jan 1, 2024
Israeli Ministry of Health approval for clinical trial testing MSX-06 for OCD and depression
Why it matters: Israeli MOH clinical trial approval enables Phase 2 recruitment. Israel serves as a "pharmaceutical beta-site" with faster regulatory timelines than FDA/EMA — successful Israeli data could support global expansion.
Recorded Events
Jan 1, 2024: regulatory-designation
Jan 1, 2023: Funding milestone
Jan 1, 2022: Company milestone
Quick Facts
- Type
- Private Biotech
- Lead Stage
- Phase II
- Website
- Visit